BioSpace News Archive

Nanoparticle drug delivery is an emerging field of life science that promises to revolutionize the field of medicine and medical technology.

Life Sciences British Columbia (LSBC) announces the companies presenting at the first annual Invest in the West presented by Amplitude Ventures on March 10, 2022.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that it has received U.S. Food and Drug Administration approval for its fifth ADMA BioCenters plasma collection facility located in Conyers, Georgia.

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced the elevation of Dr. Frank Vizesi to Chief Scientific Officer and Shaeffer Bannigan to Vice President, Product Development, Spinal Implants.

TELA Bio, Inc. (“TELA”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that it will release its fourth quarter and full year 2021 financial results on Monday, March 21, 2022.

Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that John Lunger, Chief Patient Supply Officer at Adaptimmune Therapeutics plc (“Adaptimmune”), has joined its board of directors.

Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced it will report financial results for the fourth quarter and full year 2021 on Monday, March 21, 2022, after market close.

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the U.S. Food and Drug Administration (FDA) has approved its newly developed, long-lived, recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS).

Biodesix, Inc. announced it has entered into a purchase agreement for the issuance and sale of its common stock, from time to time, of up to $50 million with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor.

Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today reported financial results and business highlights for the quarter and year ended December 31, 2021.